WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510311
CAS#: 217645-70-0 (free base)
Description: BX-471, also known as ZK-811752, is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1). BX-471 exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. BX-471 was developed Berlex and its parent company, Schering AG. BX-471 is the lead in a series of non-peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS). In March 2000, BX-471 was undergoing phase I trials for the potential treatment of autoimmune diseases.
MedKoo Cat#: 510311
Name: BX-471
CAS#: 217645-70-0 (free base)
Chemical Formula: C21H24ClFN4O3
Exact Mass: 434.1521
Molecular Weight: 434.89
Elemental Analysis: C, 58.00; H, 5.56; Cl, 8.15; F, 4.37; N, 12.88; O, 11.04
Related CAS #: 217645-70-0 (Free base) 288262-96-4 (HCl)
Synonym: BX471; BX 471; BX-471; ZK811752; ZK 811752; ZK-811752.
IUPAC/Chemical Name: (R)-1-(5-chloro-2-(2-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)-2-oxoethoxy)phenyl)urea
InChi Key: XQYASZNUFDVMFH-CQSZACIVSA-N
InChi Code: InChI=1S/C21H24ClFN4O3/c1-14-11-26(12-15-2-5-17(23)6-3-15)8-9-27(14)20(28)13-30-19-7-4-16(22)10-18(19)25-21(24)29/h2-7,10,14H,8-9,11-13H2,1H3,(H3,24,25,29)/t14-/m1/s1
SMILES Code: C[C@H]1N(C(COC2=CC=C(Cl)C=C2NC(N)=O)=O)CCN(CC3=CC=C(F)C=C3)C1
1: Vandemeulebroecke M, Lembcke J, Wiesinger H, Sittner W, Lindemann S. Assessment of QT(c)-prolonging potential of BX471 in healthy volunteers. A 'thorough QT study' following ICH E14 using various QT(c) correction methods. Br J Clin Pharmacol. 2009 Sep;68(3):435-46. doi: 10.1111/j.1365-2125.2009.03460.x. PubMed PMID: 19740402; PubMed Central PMCID: PMC2766484.
2: He M, Horuk R, Bhatia M. Treatment with BX471, a nonpeptide CCR1 antagonist, protects mice against acute pancreatitis-associated lung injury by modulating neutrophil recruitment. Pancreas. 2007 Mar;34(2):233-41. PubMed PMID: 17312463.
3: He M, Horuk R, Moochhala SM, Bhatia M. Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis. Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1173-80. Epub 2007 Jan 18. Erratum in: Am J Physiol Gastrointest Liver Physiol. 2012 Jan;302(1):G194. PubMed PMID: 17234893.
4: Horuk R. BX471: a CCR1 antagonist with anti-inflammatory activity in man. Mini Rev Med Chem. 2005 Sep;5(9):791-804. Review. PubMed PMID: 16178722.